PT  - JOURNAL ARTICLE
AU  - Johannes W.G.  Jacobs
AU  - Maxime M.A.  Verhoeven
AU  - Paco M.J.  Welsing
TI  - Unravelling the Cost of Biological Strategies in Rheumatoid Arthritis: A Kaleidoscope of Methodologies, Interpretations, and Interests
AID  - 10.3899/jrheum.201510
DP  - 2021 May 15
TA  - The Journal of Rheumatology
PG  - jrheum.201510
4099  - http://www.jrheum.org/content/early/2021/05/11/jrheum.201510.short
4100  - http://www.jrheum.org/content/early/2021/05/11/jrheum.201510.full
AB  - In this issue of The Journal of Rheumatology, Müskens, et al describe the effect of the introduction of an etanercept (ETN) biosimilar on antirheumatic medication cost1. After a Dutch rheumatology department launched this biosimilar as a substitute for the more expensive biologic ETN, the accumulated 3-monthly antirheumatic medication cost in that hospital pertaining to in- and outpatients with rheumatoid arthritis (RA), mainly consisting of cost of biologic disease-modifying antirheumatic drugs (bDMARD), decreased, as expected.